Target Patient Population: Patients with CKD and T2D
Study Overview: To assess the efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin alone in participants with chronic kidney disease and type 2 diabetes
Study Timeline: Anticipated patient participation is 8 Months, 7 visits to the clinic
Number of Patients Currently Active in the Trial: 3
